PureTech Health (LON:PRTC) Trading 9.1% Higher - Here's What Happened

Key Points

• PureTech Health's stock price increased by 9.1% during trading, reaching a high of GBX 116.80 ($1.58) before closing at GBX 116.04 ($1.57).
• The company has a market capitalization of £283.50 million and a notably high price-to-earnings ratio of 690.00.
• Insider Bharatt Chowrira acquired 167,739 shares of PureTech Health at an average cost of GBX 1 per share, signaling confidence in the company's potential.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price was up 9.1% on Friday . The company traded as high as GBX 116.80 ($1.57) and last traded at GBX 116.04 ($1.56). Approximately 866,820 shares changed hands during mid-day trading, an increase of 18% from the average daily volume of 736,782 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Performance

The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The firm has a 50-day moving average of GBX 129.46 and a 200 day moving average of GBX 129.76. The stock has a market capitalization of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of the company's stock in a transaction that occurred on Thursday, July 3rd. The stock was acquired at an average cost of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by company insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.